Indications
Adjunctive treatment in haematopoietic stem cell transplantation (HSCT) for a malignant disease
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Luxceptar
- Therapeutic area
- Graft vs Host Disease, Hematopoietic Stem Cell Transplantation
- Marketing authorisation holder
- Kiadis Pharma Netherlands B.V.
- Status
- Application withdrawn
- EMA product number
- EMEA/H/C/002397
EMA designations
- Orphan medicine
- Yes
- Conditional approval
- No
- Biosimilar
- No
- Generic
- No
- Accelerated assessment
- No
- Additional monitoring
- No
- Patient safety information
- No